Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics (MRKR)
NASDAQ:MRKR
MRKR Stock Chart & Stats
$1.71
-$0.17(-5.70%)
At close: 4:00 PM EST
$1.71
-$0.17(-5.70%)
Day’s Range― - ―
52-Week Range$0.81 - $4.07
Previous CloseN/A
Volume39.59K
Average Volume (3M)386.87K
Market Cap
$30.51M
Enterprise Value-$3.99M
Total Cash (Recent Filing)$17.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 12, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding16,673,126
10 Day Avg. Volume595,376
30 Day Avg. Volume386,866
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.50
Price to Sales (P/S)4.24
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-0.85
Enterprise Value/Gross Profit0.52
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$9.00Price Target Upside426.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityAnalyst highlights Phase 1/2 data showing compelling tumor responses and persistent presence of infused MAR‑T cells, supporting confidence in the therapy's clinical benefit.
Differentiated Mechanism Of ActionAnalyst notes MT‑601's multi‑antigen targeting could overcome antigen loss that hampers single‑target therapies, potentially improving outcomes for relapsed CAR T patients.
Regulatory Pathway PotentialAnalyst expects pivotal trial feedback and additional data for MT‑601 that could support an accelerated approval pathway in aggressive lymphoma, which would materially affect valuation if achieved.
Bears Say
Capital And Commercialization RiskAnalyst warns that commercialization challenges and capital market constraints could limit the company's ability to finance late‑stage development and scale commercial operations, putting pressure on the stock.
Competitive And Reimbursement PressureAnalyst highlights intense competition from other immunotherapies and potential reimbursement hurdles that could reduce market uptake even if clinical success is achieved.
Safety Risk From HLA MismatchAnalyst flags increased graft‑versus‑host disease risk for the MT‑401 off‑the‑shelf program because cells are only partially HLA matched, which could raise safety concerns and complicate development.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics’s price range in the past 12 months?
Marker Therapeutics lowest stock price was $0.81 and its highest was $4.07 in the past 12 months.
What is Marker Therapeutics’s market cap?
Marker Therapeutics’s market cap is $30.51M.
When is Marker Therapeutics’s upcoming earnings report date?
Marker Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 57 days.
How were Marker Therapeutics’s earnings last quarter?
Marker Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.24.
Is Marker Therapeutics overvalued?
According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued.
Does Marker Therapeutics pay dividends?
Marker Therapeutics does not currently pay dividends.
What is Marker Therapeutics’s EPS estimate?
Marker Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Marker Therapeutics have?
Marker Therapeutics has 16,673,126 shares outstanding.
What happened to Marker Therapeutics’s price movement after its last earnings report?
Marker Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went up 3.371%.
Which hedge fund is a major shareholder of Marker Therapeutics?
Currently, no hedge funds are holding shares in MRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Marker Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (426.32% Upside)
$9.00 (426.32% Upside)
Blogger Sentiment
Bullish
MRKR Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 15.5%
Last 30 Days ▲ 15.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.47%
12-Months-Change
Fundamentals
Return on Equity
-110.67%
Trailing 12-Months
Asset Growth
99.21%
Trailing 12-Months
Company Description
Marker Therapeutics
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(426.32% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
27.84%
Insiders
2.09% Mutual Funds
15.94% Other Institutional Investors
52.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---